癌症疫苗的全球市場(2022年～2028年)

全球癌症疫苗的市場規模，在預測期間內(2021年～2027年)預計以13.8％的年複合成長率大幅度成長。促進市場成長的要素，是癌症患者人口增加伴隨的全球高死亡率，和對傳統的治療技術的抵抗。治療中包含化療和放射線治療，這些可能再引起疲勞，皮膚感染，脫髮等副作用。為了克服這些，市場企業參與癌症疫苗的銷售，政府的政策和舉措的提高，成為在預測期間內市場成長的促進因素。

本報告提供全球癌症疫苗市場相關調查分析，市場區隔分析，地區分析，預測，企業簡介等資訊。

目錄

第1章 報告摘要

第2章 市場概要考察

第3章 競爭情形

• 主要企業分析
  • Bristol-Myers Squibb
  • Eli Lilly and Co.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Pfizer Inc.
• 主要策略分析
• COVID對主要企業的影響

第4章 市場決策要素

• 促進因素
• 阻礙因素
• 機會

第5章 市場區隔

• 全球癌症疫苗市場:各類型
  • 預防用疫苗
  • 治療用疫苗
• 全球癌症疫苗市場:各技術
  • 樹突狀細胞疫苗
  • 結合物疫苗
  • 不活化疫苗
  • 減毒活病毒疫苗
  • 重組的載體基礎疫苗
  • 其他
• 全球癌症疫苗市場:各終端用戶
  • 醫院、診療所
  • 研究機關
  • 製藥企業、生物科技企業
  • 其他

第6章 地區分析

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 西班牙
  • 法國
  • 其他的歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他的亞太地區
• 其他地區

第7章 企業簡介

• AduroBioTech, Inc.
• Advaxis Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Dendreon Pharmaceuticals LLC
• Dynavax Technologies Corp.
• F. Hoffmann-La Roche AG
• Generex Biotechnology Corp.
• Immunocellular Therapeutics, Ltd.
• Moderna, Inc.
• OSE Immunotherapeutics SA
• Sanofi SA
• Vaccinogen, Inc.
• Welland Medical Ltd.

Global Cancer Vaccine Market Size, Share & Trends Analysis Report by Type (Preventive Vaccines and Therapeutic Vaccines), By Technology (Dendritic Cell Vaccines, Conjugate Vaccines, Inactive Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines, and Others), By End-User (Hospitals and Clinics, Research Institutes, Pharmaceuticals & Biotechnology Companies, and Others) Forecast Period 2021-2027

The global cancer vaccine market is growing at a significant CAGR of 13.8% during the forecast period (2021-2027). The major factors that are augmenting the growth of the cancer vaccine market are the high mortality rate across the globe with the increase in the population of cancer patients and resistance to conventional treatment techniques. For instance, according to the International Agency for Research on Cancer, World Health Organization, in the US in 2020, the total mortalities due to the cancers cases was 322,028 in males and 290,362 was in females, which is expected to reach 489,580 by 2040 in male and 414,073 in female.

Treatments include chemotherapy and radiation therapy that can further lead to side effects such as fatigue, skin infection, and hair loss. To overcome this, market players are involved in launching cancer vaccines and the rising government policies and initiatives are the major factors that are fueling the market growth in the forecast period. For Instance, the Cervarix vaccine launched by GlaxoSmithKline plc had an increment of 178 % in 2020 when compared to the previous year. In 2019, the revenue generated through Ceravix by the company was $50 million which raised to $139 million in 2020. However, one of the major restraints is that the growth is likely to decline from 2022 as the patent expiry date in Europe for the vaccine is 2022 and in the US it is 2028.

However, certain factors are affecting the growth of the market. Strict regulatory policies by FDA and government authorities, high cost to maintain proper vaccine temperature, and restricting and delaying the launch of new vaccines are some of the challenges which cancer vaccine market is expected to face in the forecast period.

Impact of COVID-19 Pandemic on Global Cancer Vaccine Market

The global cancer vaccine market was negatively affected by the COVID-19 pandemic since December 2019. COVID-19 has affected around 210 countries across the globe. The COVID-19 pandemic in the major economies has disrupted the manufacturing and supply of cancer vaccines across the globe. As the number of COVID-19 cases increased, healthcare systems around the globe turned their priority to containing the disease, delaying the prevention, diagnosis, and treatment of other chronic disorders such as cancer. As a result, the cancer vaccine market is now predicted to face a negative impact. The market will witness "W" shape recovery in near future owing to the restart of key industries in major economies. Conversely, an increase in the research for the alternatives of various therapies to reduce the burden of cancer cases is estimated to provide lucrative growth opportunities to the market players.

Segmental Outlook

The market is segmented based on type, technology, and end-user. By type, the market is segmented into preventive vaccines and therapeutic vaccines. The preventive vaccine segment holds a significant market share in 2020. The preventive vaccine market growth is driven by the rising number of cancer patients across the globe. The preventive vaccine providers include Pfizer, CureVac AG, GlaxoSmithKline plc, and Janssen Global Services, LLC among others. Further, significant researches on new testing vaccines are expected to contribute to the market growth. Based on the technology segment, the market is segmented into dendritic vaccines, conjugate vaccines, inactivated vaccines, live attenuated vaccines, recombinant vector vaccines, and others. Further, based on the end-user segment, the market is segmented into hospitals and clinics, research institutes, pharmaceuticals and biotechnology companies, and others.

Global Cancer Vaccine Market Share by Type, 2020 (%)

Global Cancer Vaccine Market Share by Type

Preventive Vaccines Segment to Hold a Lucrative Share in the Global Cancer Vaccine Market

Amongst the type segment of the global cancer vaccines market, the preventive vaccine segment is projected to grow at a substantial rate over the forecast period. Vaccines that are intended to prevent cancer in healthy persons are known as preventive or prophylactic vaccines. These vaccines function by protecting against infectious pathogens that can cause or contribute to cancer. The US FDA has approved the two cancer prevention vaccines such as human papillomavirus vaccination (HPV) and the hepatitis B vaccine. Besides this, according to the National Cancer Institute, Gardasil, Gardasil 9, and Cervarix are the three vaccinations approved by the US FDA to prevent HPV infection. Gardasil and Gardasil 9 have been approved for use in the prevention of HPV-related cervical, vaginal, and anal cancer in women. Cervarix was approved for the prevention of cervical cancer in women caused by HPV.

Regional Outlooks

The global cancer vaccine market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is classified into North America (the US and Canada), Europe (UK, France, Germany, Spain, Italy, and the Rest of Europe), Asia Pacific (India, China, Japan, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East and Africa, and Latin America). North America is estimated to be the leading region in the global cancer vaccine market. The presence of most of the major companies and developed healthcare infrastructure are the factors driving the growth of the market in this region. The US accounts for the major share in this region. For instance, according to the WHO in 2020, the US had 2.28 million cancer patients.

Global Cancer Vaccine Market Growth, by Region 2021-2027

Global Cancer Vaccine Market Growth, by Region

Asia-Pacific is projected to highest Contributor to the growth of the Global Cancer Vaccine market

Asia-Pacific is anticipated to be the fastest-growing region in the global cancer vaccine market. In the region, China, South Korea, Japan, Singapore, and India are showing rapid progress. The major factors driving the growth of the market in this region are government initiatives and policies and the rise in healthcare expenditure in emerging economies. Moreover, an increase in cancer patients is expected to result in an increase in cancer vaccine market revenue in the forecast period. For instance, as per the WHO in 2020, there are more than 5.0 million new cases of cancer in China and 1.7 million cases in India. Whereas, in Japan, the total number of cancer cases was around 0.8 million in 2020. Contrarily, the mortalities due to cancer in India, China, and Japan are 1.0 million, 3.2 million, and 0.4 million respectively. The rising prevalence of cancer and mortalities due to cancer is increasing the demand for cancer vaccines during the forecast period.

Market Players Outlook

Key players of the cancer vaccine market are Bristol-Myers Squibb, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Pfizer Inc., Dendreon Pharmaceuticals LLC, and Janssen Global Services, LLC. To survive in the market these players adopt different marketing strategies such as a merger, acquisitions, product launch, and geographical expansion so on. For instance: In January 2019, GlaxoSmithKline plc acquired TESARO Inc. to strengthens GSK's pharmaceutical business and to accelerate the building of GSK's pipeline in the field of oncology. The cash agreement was done for $5.1 billion.

The Report Covers

Market value data analysis of 2019 and forecast to 2026.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global cancer vaccine market based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying who-stands-where in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Cancer Vaccine Industry
• Recovery Scenario of Global Cancer Vaccine Industry
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Bristol-Myers Squibb
    • 3.1.1.1. Overview
    • 3.1.1.2. Financial Analysis
    • 3.1.1.3. SWOT Analysis
    • 3.1.1.4. Recent Developments
  • 3.1.2. Eli Lilly and Co.
    • 3.1.2.1. Overview
    • 3.1.2.2. Financial Analysis
    • 3.1.2.3. SWOT Analysis
    • 3.1.2.4. Recent Developments
  • 3.1.3. GlaxoSmithKline plc
    • 3.1.3.1. Overview
    • 3.1.3.2. Financial Analysis
    • 3.1.3.3. SWOT Analysis
    • 3.1.3.4. Recent Developments
  • 3.1.4. Merck & Co. Inc.
    • 3.1.4.1. Overview
    • 3.1.4.2. Financial Analysis
    • 3.1.4.3. SWOT Analysis
    • 3.1.4.4. Recent Developments
  • 3.1.5. Pfizer Inc.
    • 3.1.5.1. Overview
    • 3.1.5.2. Financial Analysis
    • 3.1.5.3. SWOT Analysis
    • 3.1.5.4. Recent Developments
• 3.2. Key Strategy Analysis
• 3.3. Impact of Covid on key players

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Cancer Vaccine Market by Type
  • 5.1.1. Preventive Vaccines
  • 5.1.2. Therapeutic vaccines
• 5.2. Global Cancer Vaccine Market by Technology
  • 5.2.1. Dendritic Cell Vaccines
  • 5.2.2. Conjugate Vaccines
  • 5.2.3. Inactivated Vaccines
  • 5.2.4. Live Attenuated Vaccines
  • 5.2.5. Recombinant Vector Vaccines
  • 5.2.6. Others
• 5.3. Global Cancer Vaccine Market by End-User
  • 5.3.1. Hospitals and Clinics
  • 5.3.2. Research Institutes
  • 5.3.3. Pharmaceuticals & Biotechnology Companies
  • 5.3.4. Others

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korea
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. AduroBioTech, Inc.
• 7.2. Advaxis Inc.
• 7.3. Amgen Inc.
• 7.4. Astellas Pharma Inc.
• 7.5. AstraZeneca PLC
• 7.6. Dendreon Pharmaceuticals LLC
• 7.7. Dynavax Technologies Corp.
• 7.8. F. Hoffmann-La Roche AG
• 7.9. Generex Biotechnology Corp.
• 7.10. Immunocellular Therapeutics, Ltd.
• 7.11. Moderna, Inc.
• 7.12. OSE Immunotherapeutics SA
• 7.13. Sanofi SA
• 7.14. Vaccinogen, Inc.
• 7.15. Welland Medical Ltd.

LIST OF TABLES

1. GLOBAL CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLIONS)

2. GLOBAL PREVENTIVE VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

3. GLOBAL THERAPEUTIC VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

4. GLOBAL CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027($ MILLIONS)

5. GLOBAL DENDRITIC CELL VACCINES IN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

6. GLOBAL CONJUGATE VACCINES IN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

7. GLOBAL INACTIVATED VACCINES IN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

8. GLOBAL LIVE ATTENUATED VACCINES IN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

9. GLOBAL RECOMBINANT VECTOR VACCINES IN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

GLOBAL OTHERS VACCINES IN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

10. GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLIONS)

11. GLOBAL CANCER VACCINES IN HOSPITALS & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

12. GLOBAL CANCER VACCINES IN RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

13. GLOBAL CANCER VACCINES IN PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

14. GLOBAL CANCER VACCINES IN OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLIONS)

15. GLOBAL CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027($ MILLIONS)

• 16. NORTH AMERICAN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
• 17. NORTH AMERICAN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027($ MILLION)
• 18. NORTH AMERICAN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLION)
• 19. NORTH AMERICAN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 20. EUROPEAN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
• 21. EUROPEAN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLION)
• 22. EUROPEAN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027($ MILLION)
• 23. EUROPEAN CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 24. ASIA-PACIFIC CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
• 25. ASIA-PACIFIC CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027($ MILLION)
• 26. ASIA-PACIFIC CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLION)
• 27. ASIA-PACIFIC CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 28. REST OF THE WORLD CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027($ MILLION)
• 29. REST OF THE WORLD CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027($ MILLION)
• 30. REST OF THE WORLD CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027($ MILLION)

LIST OF FIGURES

• 1. IMPACT OF COVID-19 ON GLOBAL CANCER VACCINE MARKET, 2020-2027 ($ MILLION)
• 2. IMPACT OF COVID-19 ON GLOBAL CANCER VACCINE MARKET BY SEGMENT, 2020-2027 ($ MILLION)
• 3. RECOVERY OF GLOBAL CANCER VACCINE MARKET, 2021-2027 (%)

4. GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY TYPE, 2020 AND 2027(IN %)

5. GLOBAL CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020 AND 2027(IN %)

6. GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020 AND 2027(IN %)

7. GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2020 AND 2027(IN %)

8. US CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

9. CANADA CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

10. UK CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

11. FRANCE CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

12. GERMANY CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

13. ITALY CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

14. SPAIN CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

15. ROE CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

16. INDIA CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

17. CHINA CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

18. JAPAN CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

19. SOUTH KOREA CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

20. REST OF ASIA-PACIFIC CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)

21. REST OF THE WORLD CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLIONS)